Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early December 2024.
Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor
Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein,
Glucotrack completes first human clinical study for CBGM
Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations often seen with traditional continuous glucose monitors that measure glucose levels in interstitial fluid.
Glucotrack reports success in first human glucose monitor trial
RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring system (CGM).
Glucotrack Prices $3 Million Public Offering to Fund Expansion
At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...
Hosted on MSN2d
Glucotrack hits trial success for direct blood measuring CGM
The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...
FierceBiotech2d
Glucotrack’s 3-year diabetes sensor implant clears initial human safety trial
Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
Yahoo Finance3d
GlucoTrack, Inc. (GCTK)
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
Glucotrack, Inc. Announces 1-for-20 Reverse Stock Split
Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...
Nasdaq17d
Glucotrack, Inc. Achieves ISO 13485:2016 Certification, Enhancing Commitment to Quality in Diabetes Technology
Glucotrack, Inc., a medical technology company specializing in diabetes solutions, announced it has achieved ISO 13485:2016 certification from the British Standards Institute, marking a ...
GlucoTrack Inc trading halted, news pending
Inc trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...